TRIS

Pharmaceutical preparations, namely, beta-Hydroxy beta-methylglutaryl-CoA (HMG-CoA) reductase inhibitors used to lower LDL cholesterol and to treat hypertriglyceridemia as an adjunct to diet; cholesterol lowering medications; pharmaceutical preparations that act as central nervous system stimulants; pharmaceutical preparations, namely, neuromodulators for treatment of psychiatric disorders and disorders related to attention-deficit hyperactivity disorder; pharmaceutical preparations for the treatment of attention-deficit hyperactivity disorder (ADHD); liquid oral pharmaceutical preparations for the treatment of attention-deficit hyperactivity disorder (ADHD); solid pharmaceutical preparations for the treatment of attention-deficit hyperactivity disorder (ADHD); pharmaceutical preparations for the treatment of narcolepsy; pharmaceutical preparations for the treatment of chronic lung disease; pharmaceutical preparations for the treatment of colds; pharmaceutical preparations for the treatment of coughs; extended release liquid pharmaceutical preparations for the treatment of coughs; pharmaceutical preparations for the treatment of upper respiratory symptoms; pharmaceutical preparations for the treatment of pain

Providing information relating to therapeutic properties of pharmaceutical preparations; providing a website featuring information relating to therapeutic properties of pharmaceutical preparations